Duragesic® transdermal patch:: Postmortem tissue distribution of fentanyl in 25 cases

被引:86
|
作者
Anderson, DT [1 ]
Muto, JJ [1 ]
机构
[1] Los Angeles Cty Dept Coroner, Los Angeles, CA 90033 USA
关键词
D O I
10.1093/jat/24.7.627
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Fentanyl is a potent, short-acting narcotic analgesic widely used as a surgical anesthetic and for the control of pain when administered in the form of a transdermal patch. The success of the patch can be attributed to fentanyl's low molecular weight and its highly lipophilic nature, which enables it to be readily absorbed through the skin and subsequently distributed throughout the body. Over the past three years, the Los Angeles County Coroner's Toxicology Laboratory has encountered 25 cases involving Duragesic patches (fentanyl), and their postmortem tissue distributions are presented here. The analysis of fentanyl from postmortem specimens (3-mL or g sample size) consisted of an n-butyl chloride basic extraction followed by identification and quantitation on a gas chromatograph-mass spectrometer using the selected ion monitoring (SIM) mode. The fentanyl ions monitored were m/z 245, 146, and 189 and the internal standard, fentanyl-d5 ions, were m/z 250, 151, and 194 (quantitation ion underlined). The linear range of the assay was 1.67 μg/L to 500 μg/L with the limit of quantitation and detection of 1.67 μg/L. The postmortem tissue distribution ranges of fentanyl in the 25 fatalities were as follows: heart blood, 1.8-139 μg/L. (23 cases); femoral blood, 3.1-43 μg/L (13 cases); vitreous, +<2.0-20 μg/L (4 cases); liver, 5.8-613 μg/kg (22 cases); bile, 3.5-262 μ/L (15 cases); urine, 2.9-895 μg/L (19 cases); gastric, 0-1200 μg total (17 cases); spleen, 7.8-79 μg/kg (3 cases); kidney, 11 μg/kg (1 case); and lung, 31 μg/kg (1 case). The age of the decedents in this study ranged from 19 to 84, with an average age of 46. The modes of death included 15 accidental, 5 natural, 3 suicidal, and 2 undetermined. The main objectives of this paper are to show the prevalence of fentanyl patches in our community and to aid the forensic toxicologist with the interpretation of postmortem fentanyl levels in casework.
引用
收藏
页码:627 / 634
页数:8
相关论文
共 50 条
  • [1] Suicide by Duragesic transdermal fentanyl patch toxicity
    LoVecchio, Frank
    Ramos, Lee
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2011, 29 (01) : 131.e1 - 131.e2
  • [2] Fentanyl transdermal matrix patch (Durotep® MT Patch; Durogesic® DTrans®; Duragesic® SMAT) -: In adults with cancer-related pain
    Hoy, Sheridan M.
    Keating, Gillian M.
    DRUGS, 2008, 68 (12) : 1711 - 1721
  • [3] Urine concentrations of fentanyl and norfentanyl during application of Duragesic® transdermal patches
    Poklis, A
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2004, 28 (06) : 422 - 425
  • [4] Fentanyl-related toxicity: a summary of 25 postmortem cases
    Jin, M
    Shi, RZ
    Gock, SB
    Jannetto, PJ
    Jentzen, JM
    Wong, SH
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 235 - 235
  • [5] TOXICITY FROM TRANSDERMAL FENTANYL PATCH
    HARDWICK, WE
    CHANDLER, J
    PALMISANO, P
    KING, W
    CLINICAL RESEARCH, 1993, 41 (04): : A814 - A814
  • [6] POTENTIAL DANGERS RELATED TO TRANSDERMAL FENTANYL (DURAGESIC(R)) WHEN USED FOR POSTOPERATIVE PAIN
    BERNSTEIN, KJ
    KLAUSNER, MA
    DISEASES OF THE COLON & RECTUM, 1994, 37 (12) : 1339 - 1340
  • [7] Tissue distribution of mirtazapine (Remeron®) in postmortem cases
    Moore, KA
    Levine, B
    Smith, ML
    Saki, S
    Schames, J
    Smialek, JE
    JOURNAL OF ANALYTICAL TOXICOLOGY, 1999, 23 (06) : 541 - 543
  • [8] Fentanyl transdermal patch: are patients using it correctly?
    Vinas-Bastart, M.
    Oms-Arias, M.
    Modamio, P.
    Pedraza-Gutierrez, A.
    Lastra, C. F.
    Marino, E. L.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 301 - 302
  • [9] Fatal Transdermal Fentanyl Patch Overdose in a Child
    Hilado, Mark A.
    Getz, Ariana
    Rosenthal, Rachel
    Im, Daniel D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (01)
  • [10] Re: The fentanyl transdermal patch in the dying phase
    Kirkham, SR
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 26 (01) : 589 - 590